Medicamentele

O pagină pentru fiecare medicament. Dimensiunile efectelor, designul studiilor și populațiile în care au fost măsurate.

Peptide

Semaglutide

STEP 1 to STEP 5, SELECT, and roughly 15% mean weight loss in obesity without diabetes.

Dual agonist

Tirzepatide

SURMOUNT-1 and -2, sleep apnoea and heart failure, and about 21% mean weight loss.

Oral

Oral GLP-1

Oral semaglutide and orforglipron — the same mechanism without the injection.

Also from us

Tools and books we publish that are relevant to this page. These are ours — we say so rather than presenting them as neutral picks.

App ⏱️ LyteFast
Intermittent fasting timer with an evidence-based coach
App 🍽️ Litely
Food tracker and fasting timer for people who hate fasting apps
App 🐟 Sardines Fasting
Structured fasting protocols with a food-first approach
App 🥦 Fiberlism
Fibre tracking, because almost nobody hits the target
App 📷 SkinnyScan
Scan any meal for calories, macros and an A–E health grade
Book 📘 The Sardines Fasting Method
A food-first take on intermittent fasting: what to eat in the window, not just when to close it.
Book 📓 The SkinnyScan Guide
Decoding nutrition labels and the marketing built on top of them.
App 🌙 BioClock Sleep
Circadian-aware sleep and light tracking

Lecturi conexe

Fasting Evidence

Intermittent fasting, time-restricted eating and meal timing, judged on the trial data.

Metabolism Review

Energy expenditure, insulin resistance and metabolic adaptation, without the folklore.

Weight Loss Evidence

Diets, drugs, behaviour and maintenance — ranked by the strength of the evidence behind them.

Sleep Evidence

Sleep, circadian rhythm and the wearables that claim to measure both.

Această pagină a fost tradusă automat din engleză. Citațiile și numerele rămân neschimbate. Citește originalul în engleză dacă ceva pare ciudat. Citește originalul în engleză